Cognitive impairment is a common and disabling feature of Multiple Sclerosis (MS), including early MS, and may even predate any physical symptoms. It contributes even more to withdrawal from work than physical disability. Here, we provide an overview of cognitive impairment in MS, particularly in early MS where it is most commonly under-reported and undertreated. We address the presenting features of CI, its impact on quality of life, and its validated assessments (in particular the use of Brief International Cognitive Assessment in MS for use in a clinical setting). We review the insights radiology has given us into the pathogenesis of cognitive impairment in MS, particularly in early CI and in cognitively preserved MS patients. We review current treatments for cognitive impairment, primarily cognitive rehabilitation. We address the evidence for its associated co-morbidities, which may exacerbate or trigger CI, and should therefore be addressed early in the disease course (smoking, alcohol, mood, fatigue and potential co-existing sleep disorders, exercise, and vitamin D). The article supports the importance for early recognition and management of cognitive impairment in MS, before it becomes an established and irreversible entity.
Introduction
Cognitive impairment (CI) is identified in a large proportion (40-70%) of people with multiple sclerosis (MS), depending on the population studied, and the neuropsychological assessment used.
1 CI has a resultant negative impact on performance in everyday activities including employment status, social interactions, treatment adherence, and functional independence-in a disease where focus has traditionally been centred on the accumulation of physical disability. In fact, the presence of cognitive and psychological difficulties in people with MS, contributes even more to withdrawal from work and unemployment than physical disability. Seven years following diagnosis, only 54.4% of the MS population remain in employment. 2 This is associated with the presence of CI at, or soon after, diagnosis of MS independent of disability, fatigue, or depression. Patterns of CI in MS typically affect, information processing speed, memory (episodic, working and semantic), and executive function domains. Although Charcot first described CI in MS over 100 years ago, it has only recently remerged as a topic of interest for research. This is likely the result of the available disease modifying therapies for MS which have resulted in improved physical outcomes, and there is now increased focus on quality of life factors and cognition in particular as new therapeutics targets. Although a high prevalence of CI is acknowledged at later, progressive stages of MS, the point at which CI first manifests is not clearly defined. It is likely under-recognized at early stages We aim to critically review the literature, focusing on patterns of CI in MS, its clinical assessment, and associated radiological findings. We focus in particular this evidence in early stages of MS following diagnosis.
Patterns of cognitive impairment in MS and clinical assessment
CI is present in all MS subtypes, but is more common, and more severe in progressive, than relapsing-remitting MS. It most commonly manifests as impaired information processing speed, 5 the speed at which one can process verbal or visual information. Working memory, (the use of temporarily stored information for tasks such as reasoning) is also frequently affected. Other frequently affected domains are episodic memory, and executive functions including verbal fluency, and word list generation. 6 Aphasia, apraxia and agnosia may occur in rare cases, but are characteristically spared-even at later stages. Tests used to evaluate CI in MS, whether for routine clinical practice, or research, must be validated to ensure that they are reliable and sensitive.
Cognitive assessment instruments in the MS clinic
The quality of a battery used for assessment in MS should be determined based on the following: standardization, ability to differentiate an MS population from controls, test-re-test reliability, availability of normative data, and learning effects. The Brief Repeatable Battery of Neuropsychological tests (BRB-N) consists of five different neuropsychological tests: selective reminding, spatial recall, symbol digit modalities, paced auditory serial addition, and word list generation tests. It has been validated as a sensitive measure of early CI in MS, with a sensitivity of 71% and a specificity of 94%, in discriminating cognitively impaired from cognitively intact MS patients. It takes 45 min to administer, and requires neuropsychology-trained personnel to perform. The Minimal Assessment of Cognitive Function in MS (MACFIMS) is composed of seven different neuropsychological tests which cover five domains of cognitive function commonly affected in MS; the Paced Auditory Serial Addition test (PASAT) and the Symbol Digit Modalities test (information processing speed and working memory), the California Verbal Memory test and the revised Brief Visuospatial Memory Test (learning and memory), the Controlled Oral Word Association test (language), the Judgement of Line Orientation test (spatial processing), and the Sorting test (executive function). The battery takes 90 min, requiring neuropsychologytrained personnel. PASAT is particularly subject to learning effects when repeated, which do not typically stabilize until repeated at least 3 times in a participant. 7 Both are the most widely used neuropsychological batteries which are relevant and validated for MS. They are comparable in their discriminative validity, with equal abilities to distinguish MS patients from healthy controls. Because both are time consuming and require special materials and experienced neuropsychologists to administer and interpret, they are not used in routine clinical practice.
BICAMS: a cognitive tool for clinicians
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 8 was developed by a committee of neurologists and neuropsychologists in an attempt to develop a screening tool which could be used during the clinical assessment of a person with MS. BICAMS takes 15 min to administer, and does not require special materials. Once trained, the tool can be administered by physicians and MS nurses in a clinic visit. It assesses the cognitive domains of information processing speed, verbal, and visual memory using the Symbol Digit Modalities test, the first five recall trials of the California Verbal Memory test and the first three recall trials of the Brief Verbal Memory test (Figure 1 ), respectively. These tests were chosen by the panel with consideration of both their psychometric standards (reliability, validity and sensitivity in MS) and practical standards (ease of administration, feasibility and acceptability to patients). BICAMS is not designed to be a full cognitive assessment, but rather an accurate monitoring or screening instrument, for use in a clinical setting. It has been validated as an accurate cognitive battery in more than 28 countries.
Onset of cognitive impairment in early MS
The reported prevalence of cognitive decline at first presentation is estimated between 25% and 57% in patients with CIS. The concept of cognitive reserve may, in part, explain the variability in onset of CI amongst people with MS. Originally proposed by Stern, cognitive reserve proposes that individuals who are more cognitively efficient-whether due to their education level, occupation, or involvement in cognitively stimulating activities-can withstand more neuronal insult before manifesting CI. A higher education level has been shown to have a protective effect on CI in MS, with markers of brain atrophy and disease burden in MS in keeping with this cognitive reserve theory. 9 Pre-morbid verbal intelligence, or vocabulary, has also been studied, and seems to be protective for CI in MS. The Weschler Abbreviated Scale of Intelligence, as a marker of verbal intelligence, has been shown that the effects of brain atrophy on information processing speed, learning and episodic memory are less in those with increased pre-morbid verbal intelligence. 10 Some studies have taken multi-factorial pre-morbid markers of cognitive reserve on CI outcomes in MS; a "Cognitive Reserve Index" is based on education, verbal intelligence scores, and pre-morbid cognitive leisure activities. However, using this index, cognitive reserve did not predict cognitive decline over 1.6 years associated with brain atrophy, perhaps due to the lack of significant cognitive decline over this relatively short time period.
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Radiological associations with cognitive impairment in MS MRI is necessary in both the diagnosis of MS, and as a surrogate marker monitoring disease activity. There is a positive correlation between T2 lesion burden on MRI, and reduced neuropsychological performance, but not powerful enough to allow for prediction in any individual case. The relationship between cognitive changes and T1 or gadolinium-enhancing lesions is even less reliably well-related. These findings suggest that the presence of focal demyelinating lesions alone is not a sufficient explanation for CI.
In the earliest stages of MS, cognitive changes are typically very subtle, and this is thought to reflect compensatory mechanisms that can mask the presence or extent of CI. Compensatory cortical activations in regions involved in executive processing have been identified on functional MRI imaging (fMRI) in clinically isolated syndrome. fMRI studies have shown increased in resting state functional connectivity in frontal regions of the brain involved in the attention network, in cognitively preserved MS patients, compared with healthy controls. This appears to be an adaptive mechanism to neuronal injury, with increased cortical recruitment of cognitive related areas, and it is subsequently lost in cognitively impaired MS patients, where increased cortical activation cannot indefinitely continue and exhaustion of these adaptive mechanisms has been suggested as the cause of CI. Thalamo-cortical resting state connections appear to be particularly important early changes in CI, with increased resting state functional connectivity seen with worse cognitive performance, increasing with increased cognitive demand-this suggests the inability to compensate for microstructural thalamic damage by increasing resting state functional connectivity and therefore preventing manifestation of cognitive dysfunction. 7 In keeping with this finding, the presence of thalamic atrophy measured by third ventricular width early in MS, is a poor prognostic indicator for the development or the presence of CI. It has also been indicated as one of the earliest markers, (Figure 2 ) as well as other deep grey matter structures including the basal ganglia and the dentate nucleus, implicated in CI. 12 Other novel imaging techniques have been developed to investigate MRI parameters in MS which may correlate better with CI. Most commonly used are Magnetisation Transfer Ratio (MTR), and Diffusion Tensor Imaging (DTI). MTR compares magnetization between free and myelin-bound protons; it is therefore useful in measuring myelin and axonal density. MTR can detect subtle changes in normal-appearing white and grey matter at the earliest clinical stages of MS. In early RRMS, grey mater MTR values independently predict CI 13 years later. 13 DTI, measures the mobility of protons in axons, giving microstructural information of their integrity. DTI has given insight into the association of impaired information processing speed and attention; associated with abnormal DTI metrics in the corpus callosum, and prefrontal connecting tracts. DTI can also detect subtle changes in normal-appearing white and grey matter early on; that become more pronounced later. These measures of injury to normal appearing white and grey matter also correlate with abnormal cortical and subcortical resting state functional connectivity measures by fMRI, and subsequent whole brain atrophy, 14 supporting the theory of brain atrophy resulting secondary to injury including in normal appearing white and grey matter, by Wallerian degeneration. Brain volumetric studies show the strongest correlation with cognitive performance over conventional radiological findings, of which whole brain atrophy (measured by percentage brain volume change), is a more sensitive marker than any regional atrophy measures.
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Emerging methods for cognitive assessment in MS
Computerized batteries for the assessment of MS could solve some of the problems associated with cognitive testing in a clinical setting, in particular the time required for testing and limited access to neuropsychology services. Computers also provide exact measures of response times in tests of information processing speed. However, it may not be possible to perform for those who have muscle weakness or coordination impairments. Computerized tests also limit testing of verbal recall, with the need for a test administrator to mark verbal responses. The Automated Neuropsychology Assessment Matrix (ANAM) battery has been shown as an acceptable screening tool for CI in MS, with the ability to distinguish MS patients from healthy controls as well as CI MS patients from cognitive preserved. The battery takes 30 min to perform and tests reaction time, information processing speed, working and episodic memory. More recently, the Cognitive Drug Research (CDR) battery was developed; it has been validated for screening of CI in MS and is a potential alternative for MACFIMS and BRB-N in the clinical research setting. It takes 15-20 min to perform, but does require the use of an administrator to record verbal responses. 16 The use of saccadic eye movement paradigms, have also been used by researchers as a potential objective measure of the integrity of cognitive processing networks. Because the oculo-motor system is a widely distributed system involving many different cortical and subcortical connecting regions, it may become affected in association with CI in MS, in particular saccades, being the fastest eye movements. Anti-saccades may be used to test working memory, and are associated with more error in CI MS patients, when assessed using PASAT. Saccadic latencies are also longer in these patients. 17 Treatment strategies for cognitive impairment once identified Neuropsychological rehabilitation is currently the mainstay for treatment of CI in MS. Prior to rehabilitation; patients have indepth neuropsychological testing to accurately identify cognitive deficits. Rehabilitation aims to both increase the patient's awareness of their own CI and create mechanisms for them to manage with CI in daily life. Rehabilitation also aims to reduce cognitive deficits through cognitive retraining. A recent Cochrane review of over 20 randomized controlled trials; has shown the benefits to patients undergoing rehabilitation, with 18 of 20 studies showing significant positive effects. 18 Identifying modifiable risk factors for development of CI in early MS is important in order to prevent or slow decline. Smoking is a risk factor for worse cognition and physical outcomes; and co-existent excessive alcohol consumption accentuates these smoking effects. 19 Depression, fatigue, physical fitness, and vitamin D deficiency also have negative impact on cognition, with the strongest evidence for depression, particularly correlating with impaired information processing speed. 20 Exercise may delay the onset of CI or improve cognition in MS; this may be mediated through its anti-inflammatory immune effects. Higher physical activity levels are associated with increased grey and white matter volumes in cognitive brain regions on volumetric MRI. 21 A recent systematic review of 26 studies demonstrated physical fitness to be associated with better cognitive function in MS. The evidence for the benefits of exercise on CI once present in MS is conflicting, but structured physical activity rehabilitation programs may contribute to cognitive stability or improvement in the MS population. 22 Once established, there is no evidence that CI is amenable to medical therapy. Stimulants such as amantadine, methylphenidate, and modafinil have shown no benefits. There have been no significant benefits associated with anticholinesterases used in Alzheimer's disease such as donepezil and rivastigmine. The potassium channel blocker, fampridine, was also unsuccessful. Limited evidence exists for the effects of disease modifying treatments on CI. Randomized controlled trials typically only use the paced auditory serial addition test to assess cognition, and CI is generally a secondary outcome-therefore inappropriate patient inclusion criteria and sample sizes are used to accurately assess it. 23 High dose simvastatin therapy has been shown to reduce annualized rates of brain atrophy by 43%, probably secondary to both the anti-inflammatory, and neuroprotective effects of this drug. 24 Emerging monoclonal antibodies should also be tested for their cognitive, and brain atrophy effects (daclizumab, ocrelizumab, ofatumumab). Recent evidence suggests that sleep disorders occur at a higher prevalence in people with MS and contribute to CI; research in this area could offer a novel therapeutic approach in MS CI. 25 
Conclusions
CI is an important aspect of MS, with resulting functional handicaps and adverse effects on patients' quality of life. There is clear evidence that the onset of CI may pre-date physical disability, and is present even prior to the initial overt symptoms of MS; it is an important aspect to be addressed from first presentation. However, the prevalence of CI at disease onset and its longer term implications, remain unclear.
Further studies of cognitive function at diagnosis and in early disease course are required to identify the true prevalence of cognitive dysfunction at diagnosis, its incidence thereafter, factors contributing to its development and insight into its pathogenesis. MRI studies at early stages could allow us to identify early markers predicative of or associated with CI. Conventional MRI measures are not sufficient in measures of mechanisms for CI. New MRI measures require further study to allow neurologists to reliably monitor and predict changes relevant to cognition in a clinical setting.
The heterogeneity of the neuropsychological tests previously used to assess cognition in MS has undoubtedly contributed to the considerable variation in the reported prevalence of cognitive deficits. Future neuropsychological research should use practical, validated and accurate screening tools that are also applicable in a clinical setting, such as BICAMS.
